marked.bio

B7-H3 ADC ยท ADC

DB-1311

1 active trials across 2 of our biomarkers, targeting B7-H3. Not approved for any biomarker on marked.bio yet.

Also known as BNT324.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of DB-1311.

  1. DualityBio 1

Trials

1 of 1 trials shown

  1. DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

    Recruiting Phase 2 DualityBio Started 2025Primary completion 2030-06 NCT06953089

    DB-1311pumitamigDB-1305

    Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations

    ALK fusionHER2-low / ultralow (IHC 1+ or 2+/ISH-)Solid Tumors